Evidence map›Paper›PMID 42043737›Full record

ReviewStem cell reviews and reports2026

Thrombopoietin Receptor MPL in Hematopoiesis and Myeloproliferative Neoplasms: Physiological Roles and Pathogenic Mechanisms.

Shujing Zhang, Muhammad Sameer Ashaq, Miaomiao Xu, Meiqi Guo, Lingling Wang, Zhuoran Li, Yi Wang, Yufeng Huang, Yuan Li, Baobing Zhao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shujing ZhangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Muhammad Sameer AshaqState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Miaomiao XuState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Meiqi GuoState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Lingling WangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Zhuoran LiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Yi WangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Yufeng HuangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Yuan LiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. liyuan23@sdu.edu.cn.
Baobing ZhaoState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. baobingzh@sdu.edu.cn.

Funding

key Program of Innovation Improvement of Small and Medium-sized Enterprises of Shandong Province in China 2023TSGC0717National Key Research and Development Program of China 2024YFC2510500National Natural Science Foundation of China 82200989Natural Science Foundation of Shandong Province ZR2024MH065
6 · The paper itself

Abstract

MPL (myeloproliferative leukemia virus) is a type I transmembrane glycoprotein acting as the receptor for thrombopoietin (TPO). Increasing evidence indicates that MPL is essential for stem cell maintenance and megakaryopoiesis. Activating mutations in MPL have been identified as the major driver mutations of myeloproliferative neoplasms (MPNs) characterized by excessive proliferation of multiple lineages. Given its dual role in hematopoiesis and MPN pathogenesis, studies of MPL reveal the imbalance between stem cell homeostasis and malignant proliferation. Here, we summarize MPL’s physiological functions and pathogenic roles, with the aim to provide novel insights into disease mechanisms and potential therapeutic strategies.

Indexed as

HematopoiesisMyeloproliferative DisordersReceptors, ThrombopoietinAnimalsHematopoietic Stem CellsHumansMutationSignal TransductionThrombopoietinMPL protein, humanReceptors, ThrombopoietinThrombopoietinHematopoietic stem cellsMegakaryopoiesisMPLMPL mutationsMyeloproliferative neoplasms (MPNs)TPO-MPL axis

Identifiers

PMID42043737

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.